Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

2.

A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient.

Tombal B.

Urol Int. 2009;83(4):373-8. doi: 10.1159/000251174. Epub 2009 Dec 8. Review.

3.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.

N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.

4.

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, Paszat LF.

J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.

5.

Quality of life and satisfaction with outcome among prostate-cancer survivors.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT.

N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.

6.

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Shahani S, Braga-Basaria M, Basaria S.

J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18. Review.

PMID:
18349064
7.

Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?

Higano CS.

Nat Clin Pract Urol. 2008 Jan;5(1):24-34. doi: 10.1038/ncpuro0995. Review.

PMID:
18185511
8.

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.

Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A.

Lancet. 2007 Aug 25;370(9588):657-66. Review. Erratum in: Lancet. 2012 Sep 1;380(9844):806.

PMID:
17720017
9.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

10.

Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW.

J Clin Oncol. 2007 Jun 10;25(17):2420-5.

PMID:
17557956
11.

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.

Israeli RS, Rosenberg SJ, Saltzstein DR, Gottesman JE, Goldstein HR, Hull GW, Tran DN, Warsi GM, Lacerna LV.

Clin Genitourin Cancer. 2007 Mar;5(4):271-7.

PMID:
17553207
12.

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.

Greenspan SL, Nelson JB, Trump DL, Resnick NM.

Ann Intern Med. 2007 Mar 20;146(6):416-24.

PMID:
17371886
13.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.

J Clin Oncol. 2007 Mar 20;25(9):1038-42.

14.

Androgen deprivation in veterans with prostate cancer: implications for skeletal health.

Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.

Ann Pharmacother. 2006 Dec;40(12):2107-14. Epub 2006 Nov 28.

PMID:
17132807
15.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
16.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

PMID:
16921050
17.

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.

J Urol. 2006 Sep;176(3):972-8; discussion 978.

PMID:
16890673
18.

Managing complications of androgen deprivation therapy for prostate cancer.

Holzbeierlein JM.

Urol Clin North Am. 2006 May;33(2):181-90, vi. Review.

PMID:
16631456
19.

Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.

Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U.

BJU Int. 2006 Jul;98(1):20-7. Epub 2006 Mar 23. Review.

20.

Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS.

Arch Intern Med. 2006 Feb 27;166(4):465-71.

Supplemental Content

Support Center